NasdaqGS - Delayed Quote USD

Recursion Pharmaceuticals, Inc. (RXRX)

4.5600
+0.3100
+(7.29%)
At close: May 16 at 4:00:00 PM EDT
4.3100
-0.25
(-5.48%)
Pre-Market: 5:45:41 AM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
59,815
58,488
43,876
39,681
10,000
Cost of Revenue
55,901
45,238
42,587
48,275
0
Gross Profit
3,914
13,250
1,289
-8,594
10,000
Operating Expense
577,946
492,254
351,349
237,133
192,775
Operating Income
-574,032
-479,004
-350,060
-245,727
-182,775
Net Non Operating Interest Income Expense
15,208
14,186
19,019
6,199
-2,879
Other Income Expense
-16,457
30
-1,087
52
-825
Pretax Income
-575,281
-464,788
-332,128
-239,476
-186,479
Tax Provision
-506
-1,127
-4,062
0
0
Net Income Common Stockholders
-574,775
-463,661
-328,066
-239,476
-186,479
Diluted NI Available to Com Stockholders
-574,775
-463,661
-328,066
-239,476
-186,479
Basic EPS
-1.80
--
-1.58
-1.36
-1.49
Diluted EPS
-1.80
--
-1.58
-1.36
-1.49
Basic Average Shares
315,895.3020
--
207,853.7020
175,537.4870
125,348.1100
Diluted Average Shares
315,895.3020
--
207,853.7020
175,537.4870
125,348.1100
Total Operating Income as Reported
-574,032
-479,004
-350,060
-245,727
-182,775
Total Expenses
633,847
537,492
393,936
285,408
192,775
Net Income from Continuing & Discontinued Operation
-574,775
-463,661
-328,066
-239,476
-186,479
Normalized Income
-574,775
-463,661
-328,066
-239,476
-185,652
Interest Income
17,268
15,758
19,116
6,254
73
Interest Expense
2,060
1,572
97
55
2,952
Net Interest Income
15,208
14,186
19,019
6,199
-2,879
EBIT
-573,221
-463,216
-332,031
-239,421
-183,527
EBITDA
-524,773
-426,722
-307,629
-227,665
-175,122
Reconciled Cost of Revenue
55,901
45,238
42,587
48,275
0
Reconciled Depreciation
48,448
36,494
24,402
11,756
8,405
Net Income from Continuing Operation Net Minority Interest
-574,775
-463,661
-328,066
-239,476
-186,479
Total Unusual Items Excluding Goodwill
--
--
0
0
-827
Total Unusual Items
--
--
0
0
-827
Normalized EBITDA
-524,773
-426,722
-307,629
-227,665
-174,295
Tax Rate for Calcs
0
0
0
0
0
Tax Effect of Unusual Items
0
0
0
0
0
12/31/2021 - 4/16/2021

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

CRSP CRISPR Therapeutics AG
38.77
+6.77%
 
ABSI Absci Corporation
2.8800
-2.70%
 
VKTX Viking Therapeutics, Inc.
28.43
+3.76%
 
SMMT Summit Therapeutics Inc.
23.87
+3.38%
 
IOVA Iovance Biotherapeutics, Inc.
1.6600
-5.68%
 
NTLA Intellia Therapeutics, Inc.
8.50
+5.26%
 
MRNA Moderna, Inc.
24.86
+5.12%
 
SRPT Sarepta Therapeutics, Inc.
36.43
+3.29%
 
SEPN Septerna, Inc.
9.84
-2.77%
 
TNXP Tonix Pharmaceuticals Holding Corp.
28.00
+21.21%